Press Release for Financial Results Q1 FY 27

Date: August 12, 2026 BSE Limited National Stock Exchange of India Limited Corporate Relation Department Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block-G, Dalal Street, Bandra-Kurla Complex, Mumbai - 400001. Bandra (East), Mumbai - 400051. Scrip Code: 524404 Symbol: MARKSANS Sub: Press Release Dear Sir/Madam, Kindly find enclosed herewith a Press Release in relation to the Un-audited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026. Further, as per Regulation 46 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the said press release will also be available on the website of the Company i.e., https://www.marksanspharma.com/press-release.html. We request you to take the aforesaid on record. Thanking You. Yours faithfully, For Marksans Pharma Limited Harshavardhan Panigrahi Company Secretary Encl: As above Marksans Pharma Ltd. 11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 Tel.: +91 22 4001 2000 E-mail: companysecretary@marksanspharma.com www.marksanspharma.com Q1FY27 Financial Results Marksans Pharma delivers record Q1FY27 — Profitability at all-time highs, cash crosses ₹1,000 crore EBITDA rises 113% YoY to ₹213 crore; PAT grows 174% YoY to ₹159 crore; UK & Europe records highest-ever quarterly revenue of ₹356 crore Mumbai, August 12, 2026 – Marksans Pharma Ltd. (NSE: MARKSANS; BSE Code: 524404) reported the financial results for the quarter ended on June 30, 2026. Mark Saldanha, Managing Director of the Company, said, “Q1FY27 has been a strong start to the year, with an all-time high quarterly EBITDA of ₹213 crore and PAT of ₹159 crore, reflecting the strength of our underlying business and our continued focus on profitable growth. UK & Europe delivered their highest-ever quarterly revenue of ₹356 crore, growing at 74.7% YoY. More importantly, Europe is emerging as a significant new growth engine for the Group, with the acquisition of QliniQ and the establishment of our front-end presence across the region. QliniQ contributed ₹44 crore in Q1FY27, marking an important first step in our European expansion. We also crossed ₹1,000 crore in cash balance for the first time, closing the quarter at ₹1,058 crore, despite the recent acquisitions of QliniQ and ABCnow. This provides us with the financial strength and flexibility to continue investing in organic growth while pursuing calibrated inorganic opportunities. Looking ahead, our focus is clear: to carry this momentum forward, scale our businesses across geographies, accelerate new launches and further strengthen our European platform. We believe the combination of broad-based growth, expanding margins and a strong balance sheet positions Marksans well for the next phase of sustainable growth.” Q1FY27 Financial Highlights ▪ Operating Revenue stood at Rs. 841 cr., up by 35.6% YoY ▪ Gross profit came in at Rs. 497 cr., up by 38.9% YoY, with a gross margin of 59.1% ▪ EBITDA stood at Rs. 213 cr., up by 112.8% YoY, with an EBITDA margin of 25.3% ▪ PAT stood at Rs. 159 cr., up by 173.9% YoY, with a net margin of 18.4% ▪ EPS was at Rs. 3.5 Business Highlights US Market ▪ US & North America Formulation business reported revenues of Rs. 377 cr. in Q1FY27, up 15.1% YoY ▪ Largest market, contributing ~45% of consolidated revenue. YoY growth supported by a healthy order book, with new launches supporting the pipeline UK and Europe Market ▪ Revenues from the UK & Europe Formulation business stood at Rs. 356 cr. in Q1FY27, up 74.7% YoY — the highest-ever quarterly revenue for the region ▪ Strongest quarter for the UK, supported by new launches and continued market-share gains, with a strong order pipeline supporting the outlook ▪ EU revenue commenced ahead of the Q2FY27 timeline, with QliniQ B.V. (Netherlands) contributing Rs. 44 cr. in Q1FY27 Australia and New Zealand Market ▪ Australia and New Zealand businesses reported revenues of Rs. 88 cr. in Q1FY27, up 53.7% YoY. Growth supported by continued portfolio expansion and new product launches RoW Market ▪ RoW business reported revenues of Rs. 20 cr. in Q1FY27, down 36.8% YoY and up 6.0% QoQ— the first sequential improvement in four quarters ▪ Middle East shipments were impacted by delays; improving geopolitical conditions could support recovery in the coming quarters Other Highlights ▪ Cash generated from operations at ₹ 185 cr during Q1FY27 ▪ Net Capex of ₹ 33 cr incurred during Q1FY27; free cash flow of ₹ 152 cr ▪ Working capital cycle ~132 days for Q1FY27, improved from ~159 days in Q1FY26 ▪ Cash balance of ₹ 1,058 cr as on 30th June 2026; net cash of ₹ 1,031 cr ▪ Research & development (R&D) spends at ₹ 23 cr in Q1FY27, 2.8% of consolidated revenue ▪ Completed the acquisition of 100% of QliniQ B.V and ABCnow in Europe. ▪ India Ratings and Research (Fitch Group) revised the outlook on the Company’s bank loan facilities to Positive from Stable; ratings affirmed at IND AA-/IND A1+ Business Performance Consolidated profit and loss statement: Particulars Q1FY27 Q1FY26 Q4FY26 YoY QoQ Operating Revenue 840.8 620.0 856.1 35.6% -1.8% Gross Profit 497.3 358.2 465.5 38.9% 6.8% Gross margin 59.1% 57.8% 54.4% 138 bps 478 bps EBITDA 213.0 100.1 195.4 112.8% 9.0% EBITDA Margin 25.3% 16.1% 22.8% 919 bps 251 bps PAT 159.4 58.2 149.0 173.9% 7.0% Net Margin 18.4% 9.3% 16.7% 910 bps 168 bps EPS (Rs.) 3.5 1.3 3.3 169.5% 6.1% All figures in Rs. Cr. unless otherwise stated Note: 1) Net Income Margin = Net profit / Total Income (Revenue from operations + Other Income) Business-wise performance: Particulars Q1FY27 Q1FY26 YoY Q4FY26 QoQ Mix US & North America 377.2 327.6 15.1% 406.2 -7.1% 44.9% UK and Europe 356.0 203.8 74.7% 307.7 15.7% 42.3% Australia & NZ 87.6 57.0 53.7% 123.4 -29.0% 10.4% Rest of World (ROW) 20.0 31.6 -36.8% 18.9 6.0% 2.4% Revenue from operations 840.8 620.0 35.6% 856.1 -1.8% 100.0% All figures in Rs. Cr. unless otherwise stated Earnings Conference Call: There will be an Earnings conference call at 4:30 pm IST on August 13, 2026, during which the leadership team will discuss the financial performance and take questions. A transcript of the conference call will be available at www.marksanspharma.com. Date and Time August 13, 2026, at 4:30 pm IST Diamond pass link Link Primary Access Numbers +91 22 6280 1384, +91 22 7115 8285 International Toll-Free Numbers US: 18667462133 UK: 08081011573 Singapore: 8001012045 Hong Kong: 800964448 About Marksans Pharma Ltd Marksans Pharma Limited (www.marksanspharma.com) headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Antidiabetic, Pain Management, Gastroenterological and Anti-allergies. The company is marketing these products globally. Disclaimer Certain statements in this press release may contain forward-looking statements, including, but not limited to, statements regarding the Company’s business strategies, operations, financial condition, and future performance. These forward-looking statements are based on current expectations, assumptions, and estimates, and are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law. Contact Information Registered Office Jitendra Sharma, CFO 11th Floor, "GRANDEUR” Marksans Pharma Ltd Off Veera Desai Extension Road Tel: +91 022 40012000 Oshiwara, Andheri West jitendra@marksanspharma.com Mumbai, Mah [Showing first 8,000 characters — download PDF for full document]